16th Oct 2025 14:28
(Alliance News) - Fusion Antibodies PLC on Thursday said it remains on plans with its strategic goals as it anticipates a stronger second financial half.
The Belfast-based contract researcher that provides discovery, design and optimisation services for therapeutic antibodies reported revenue of GBP838,000 in the six months to September 30, its first financial half, down from GBP1.2 million a year earlier but up from GBP755,000 in the second half of financial 2025.
Gross margin improved to 30% from 22%, reflecting better operational efficiency.
Fusion expects a stronger second half supported by a solid order book and improved market sentiment.
The company highlighted a new US patent covering its OptiMAL library design, continued collaboration with the National Cancer Institute, and multiple new humanisation contracts. Cash as at September 30 stood at GBP251,000, in line with management expectations.
Chair Simon Douglas said: "Cash continues to be carefully managed and, as set out in the company's financial 2025 results announced on 4 September 2025, based on internal estimates the company has a cash runway into financial 2027 and remains on plan with our strategic goals including the launch of OptiMAL in December which we believe will herald a new stage in the company's development and open up new markets and revenues."
Fusion Antibodies shares rose 4.9% to 13.90 pence each on Thursday afternoon in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Fusion Antibodies